Navigation Links
TesoRx and CoreRx Announce Joint Venture to Manufacture First-in-Class Oral Testosterone Drug
Date:9/3/2013

Menlo Park, CA and Clearwater, FL (PRWEB) September 03, 2013

TesoRx Pharma, LLC and CoreRx, Inc. today announced a manufacturing joint venture to produce TSX-002, a first-in-class oral testosterone drug targeting the $2.5Billion low testosterone market. TesoRx’s novel, proprietary formulation orally delivers therapeutic levels of unmodified testosterone in a safe and convenient manner. The company will be commencing its final Phase 3 Clinical Study in Q1 of 2014.

“This joint venture solidifies our ability to manufacture TSX-002 to the highest standards in an environment that can easily scale from our current level through Phase 3 and, ultimately, commercial release,” said Ramachandran “TR” Thirucote, Ph.D., CEO of TesoRx. “The CoreRx team has set itself apart with its service commitment and innovation, making them an obvious choice as TesoRx moves to the next phase of development.”

“This project represents a significant expansion in both the size and mission of CoreRx,” said Todd R. Daviau, President and CEO. “An oral therapy is long overdue in the treatment of male hormone deficiency and is the cornerstone of TesoRx’s current portfolio. We are happy to have been chosen as TesoRx’s development partner and are looking forward to this long-term manufacturing project with TesoRx.”

The acquisition of the Myerlake II site will add approximately 47,000 sq.ft. of additional manufacturing and office space. TesoRx plans to begin construction in the buildings across from CoreRx’s current 35,000 sq.ft. facility in the ICOT Center campus. It will house several additional suites dedicated to process development, clinical trial manufacturing and commercial manufacturing of hormone products.

Work on the expansion has already begun and should be completed by the middle of Q2 2014.

About TesoRx, Inc.
TesoRx is a privately held pharmaceutical company focused on the development of a first-in-class un
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
2. New Thermoelectric Peltier Cooler Announced by Oven Industries
3. JULABO USA Inc. Announces Update on Product Finder Tool
4. ATCC Announces Creation of Biomaterial Contributor Network
5. Suria Plastic Surgery Announces an Open House at Their Plantation, Florida Office
6. New Embedded Temperature Controllers Announced by Oven Industries
7. SCD-iBIO Announces Second International Forum on Commercializing Global Green
8. Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO
9. Pipette.com Has Announced Their Universal Pipette Filter Tip Promotion to Benefit Labs Dealing With Budget Cuts
10. EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
11. Velocity Pharmaceutical Development and Tigercat Pharma Inc. Announce Submission of IND Application for VPD-737
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DuPont Pioneer and Perdue AgriBusiness ... double the acreage contracted for Plenish® high oleic ... crush facility in Salisbury, Md. The high oleic ... several markets including foodservice and food manufacturers looking ... For the 2015 growing season, Perdue Agribusiness will ...
(Date:10/25/2014)... A new way to produce engineered ... current skin grafting technologies, it also speeds up the ... outlined in the October issue of STEM CELLS Translational ... injuries that result from severe burns and chronic wounds. ... regenerative elements. These wounds heal by contraction, with epithelization ...
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
Breaking Biology Technology:DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... dollars, QUEBEC CITY, Nov. 12 /PRNewswire-FirstCall/ - ... a global biopharmaceutical company focused on,endocrine therapy and ... agreement to sell to Cowen Healthcare Royalty Partners, ... of Cetrotide(R) covered by,its license agreement with Merck ...
... Pasteur and Chumakov Institute Russian Academy Medical Sciences, ... ... National "Project Health", PARIS, November 12 ... Russia has,chosen inactivated polio vaccine (IPV) from Sanofi Pasteur for ...
... Standard & Poor,s will make the,following changes to the S&P 500 and S&P ... GGP) will be removed from the S&P 500 ... today,s close of trading General Growth Properties had a ... in the index., -- S&P MidCap 400 constituent Cephalon Inc. ...
Cached Biology Technology:AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 2Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 3Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 4Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 5Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants 6Standard & Poor's Announces Changes to U.S. Indices 2Standard & Poor's Announces Changes to U.S. Indices 3
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
(Date:10/15/2014)... 2014 Sandata Technologies, LLC, an industry ... care, today announced it released a case study ... Visit Verification™ Solution (EVV™)  for Quality Care Services, ... company founded in 1996 and has five locations ... The study details the challenges facing Quality ...
(Date:10/15/2014)... pneumonia in female mice to an enzyme activated by ... more resistant to respiratory infections than males. Now, an ... to bacterial pneumonia in female mice is linked to ... show that this enzyme is ultimately activated by the ... team, lead by Professor Lester Kobzik at the Harvard ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... University of Alberta researchers discover that animals zig when ... told them. , In studying the spatial memory of ... to discover the birds contradicting prior research that showed ... reveal a different pattern. Previously, only animals that had ...
... study suggests that a suspect gene may increase susceptibility ... processing negative emotion. People with the depression-linked gene variant ... mood-regulating circuit. How well the circuit was connected accounted ... at the National Institute of Health's (NIH) National Institute ...
... billion neurons, and each has hundreds of connections with ... essential to understanding brain function, and the task is ... approach to mapping neuron connectivity published in PLoS Computational ... of Neuroscience at the University of Minnesota, the task ...
Cached Biology News:Chickadees can help humans get their bearings 2Depression gene may weaken mood-regulating circuit 2Depression gene may weaken mood-regulating circuit 3